MacroGenics, Inc.
NASDAQ: MGNX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eric Risser
- Employees
- 300
- Headquarters
- Rockville, United States
- IPO year
- 2013
- Market cap
- $303.8M
- Website
- http://www.macrogenics.com
Loading MGNX…
Loading profile data…Frequently asked questions about MGNX
What does MacroGenics, Inc. (MGNX) do?
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of...
Where does MGNX trade?
MacroGenics, Inc. (MGNX) trades on the NASDAQ.
What sector is MGNX in?
MacroGenics, Inc. (MGNX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MacroGenics, Inc.?
Eric Risser is the chief executive officer of MacroGenics, Inc. (MGNX).
Where is MacroGenics, Inc. headquartered?
MacroGenics, Inc. is headquartered in United States.
Does MGNX pay a dividend?
MacroGenics, Inc. (MGNX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MGNX go public?
MacroGenics, Inc. (MGNX) completed its initial public offering in 2013.